BMY Stock Cash Flow Statements

Bristol-Myers Squibb Quarterly Cash Flow Statements Chart

Quarterly

Annual

Stock-Based Compensation

Operating Cash Flow

Investing Cash Flow

Financing Cash Flow

Free Cash Flow

Capital Expenditure

Bristol-Myers Squibb Quarterly Cash Flow Statements Table

Quarterly

Annual

Unit: USD	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31	2017-12-31	2017-09-30	2017-06-30	2017-03-31	2016-12-31	2016-09-30	2016-06-30	2016-03-31	2015-12-31	2015-09-30	2015-06-30	2015-03-31	2014-12-31	2014-09-30	2014-06-30	2014-03-31	2013-12-31	2013-09-30	2013-06-30	2013-03-31	2012-12-31	2012-09-30	2012-06-30	2012-03-31	2011-12-31	2011-09-30	2011-06-30	2011-03-31	2010-12-31	2010-09-30	2010-06-30	2010-03-31

cash flows from operating activities:
net earnings/	1,313,000,000	2,462,000,000															1,061,000,000	2,029,000,000
adjustments to reconcile net earnings/(loss) to net cash from operating activities:
depreciation and amortization	1,011,000,000	1,012,000,000	1,880,000,000	2,592,000,000	2,596,000,000	2,532,000,000	2,464,000,000	2,435,000,000	2,432,000,000	2,429,000,000	2,521,000,000	2,588,000,000	2,583,000,000	2,584,000,000	2,579,000,000	2,727,000,000	2,712,000,000	2,668,000,000	2,690,000,000	2,655,000,000	2,558,000,000	2,477,000,000	1,236,000,000	171,000,000	169,000,000	170,000,000	172,000,000	165,000,000	157,000,000	143,000,000	197,000,000	188,000,000	211,000,000	193,000,000	122,000,000	105,000,000	90,000,000	65,000,000	76,000,000	105,000,000	91,000,000	104,000,000	103,000,000	112,000,000	115,000,000	137,000,000	181,000,000	180,000,000	189,000,000	213,000,000	199,000,000
deferred income taxes	-437,000,000	223,000,000	-791,000,000	-256,000,000	-331,000,000	-711,000,000	-1,327,000,000	-327,000,000	-1,086,000,000	-548,000,000	-624,000,000	-645,000,000	-782,000,000	-687,000,000	-1,266,000,000	-32,000,000	-163,000,000	68,000,000	-436,000,000	54,000,000	1,418,000,000	-53,000,000	-337,000,000	-500,000,000	-89,000,000	2,000,000	247,000,000	-124,000,000	-197,000,000	160,000,000	727,000,000	262,000,000	91,000,000	-70,000,000	296,000,000	-183,000,000	-71,000,000	-246,000,000	-398,000,000	110,000,000	-52,000,000	-7,000,000	-485,000,000	-93,000,000	-74,000,000	110,000,000	-82,000,000	-74,000,000	-153,000,000	-182,000,000	-493,000,000									3,000,000	7,000,000	90,000,000
stock-based compensation	137,000,000	144,000,000	120,000,000	129,000,000	125,000,000	133,000,000	127,000,000	132,000,000	137,000,000	122,000,000	119,000,000	115,000,000	116,000,000	107,000,000	133,000,000	142,000,000	157,000,000	151,000,000	171,000,000	185,000,000	213,000,000	210,000,000	284,000,000	56,000,000	48,000,000	53,000,000	53,000,000	62,000,000	51,000,000	55,000,000	50,000,000	50,000,000	54,000,000	45,000,000	56,000,000	48,000,000	54,000,000	47,000,000	59,000,000	63,000,000	59,000,000	54,000,000	66,000,000	48,000,000	50,000,000	49,000,000	51,000,000	45,000,000	46,000,000	49,000,000	46,000,000									47,000,000	49,000,000	47,000,000
impairment charges			1,953,000,000	139,000,000	870,000,000	1,000,000	29,000,000	159,000,000	47,000,000	20,000,000	35,000,000	61,000,000	42,000,000	41,000,000	15,000,000	613,000,000	240,000,000	339,000,000	1,072,000,000	15,000,000	63,000,000	53,000,000	16,000,000	9,000,000	129,000,000	45,000,000	16,000,000	6,000,000	24,000,000	80,000,000	109,000,000	4,000,000	141,000,000	78,000,000	33,000,000	7,000,000	49,000,000	19,000,000	168,000,000	4,000,000	7,000,000	13,000,000	15,000,000	28,000,000	311,000,000	47,000,000	34,000,000	2,000,000	1,000,000	3,000,000	62,000,000	1,830,000,000	192,000,000	96,000,000	0	13,000,000	0	15,000,000
divestiture gains and royalties	-293,000,000	-292,000,000	-281,000,000	-288,000,000	-270,000,000	-280,000,000	-245,000,000	-222,000,000	-223,000,000	-194,000,000	-243,000,000	-208,000,000	-225,000,000	-387,000,000	-222,000,000	-160,000,000	-167,000,000	-135,000,000	-213,000,000	-191,000,000	-122,000,000	-173,000,000	-179,000,000	-1,356,000,000	-154,000,000	-166,000,000	-170,000,000	-325,000,000	-242,000,000	-255,000,000	-160,000,000	-135,000,000	-135,000,000	-276,000,000	-105,000,000	-155,000,000	-420,000,000	-507,000,000
acquired iprd	1,507,000,000	188,000,000	30,000,000	262,000,000	132,000,000	12,949,000,000	600,000,000	80,000,000	158,000,000	75,000,000	52,000,000	30,000,000	400,000,000	333,000,000
equity investment (gains)/losses	22,000,000	78,000,000	205,000,000	-12,000,000	-107,000,000	-102,000,000												-601,000,000	-504,000,000
contingent consideration fair value adjustments											-10,000,000	0	0	1,000,000	-32,000,000	0	0	-510,000,000	-1,160,000,000	-988,000,000	-165,000,000	556,000,000
other adjustments	-12,000,000	10,000,000	-29,000,000	103,000,000	-2,000,000	22,000,000	48,000,000	269,000,000	-13,000,000	4,000,000	54,000,000	-40,000,000	-30,000,000	248,000,000	-26,000,000	-36,000,000	-29,000,000	233,000,000	-37,000,000	-48,000,000	-50,000,000	-42,000,000	-1,000,000	-7,000,000	-8,000,000	-6,000,000	-1,000,000	-16,000,000	2,000,000	-29,000,000	-16,000,000	9,000,000	66,000,000	33,000,000	12,000,000	-32,000,000	-14,000,000	-10,000,000	288,000,000	-365,000,000
changes in operating assets and liabilities:
receivables	-484,000,000	15,000,000	143,000,000	661,000,000	-1,019,000,000	479,000,000	-508,000,000	-247,000,000	-65,000,000	-175,000,000	-106,000,000	-674,000,000	-669,000,000	786,000,000	-168,000,000	-260,000,000	-693,000,000	67,000,000	-290,000,000	-159,000,000	546,000,000	-743,000,000	318,000,000	127,000,000	71,000,000	236,000,000	-207,000,000	-334,000,000	-107,000,000	219,000,000	108,000,000	-85,000,000	-208,000,000	-246,000,000	93,000,000	-44,000,000	-428,000,000	-424,000,000	-356,000,000	-319,000,000	-176,000,000	-91,000,000	-186,000,000	-35,000,000	24,000,000	-55,000,000	59,000,000	-159,000,000	-86,000,000	-318,000,000	5,000,000	99,000,000	652,000,000	-108,000,000	-68,000,000	176,000,000	-237,000,000	-91,000,000	-148,000,000	-68,000,000	255,000,000	-309,000,000
inventories	4,000,000	-169,000,000	175,000,000	-218,000,000	-225,000,000	-218,000,000	-197,000,000	-256,000,000	-16,000,000	-282,000,000	-41,000,000	-16,000,000	-13,000,000	1,000,000	-128,000,000	30,000,000	5,000,000	106,000,000	101,000,000	481,000,000	642,000,000	1,448,000,000	470,000,000	-35,000,000	-7,000,000	35,000,000	-64,000,000	-30,000,000	-118,000,000	-4,000,000	-36,000,000	65,000,000	13,000,000	-71,000,000	-45,000,000	4,000,000	-67,000,000	-44,000,000	-134,000,000	69,000,000	111,000,000	51,000,000	-92,000,000	-5,000,000	-13,000,000	-144,000,000	-37,000,000	165,000,000	-10,000,000	-163,000,000	32,000,000	35,000,000	-102,000,000	-68,000,000	-43,000,000	96,000,000	-162,000,000	-84,000,000	193,000,000	-49,000,000	-13,000,000	25,000,000
accounts payable	13,000,000	-85,000,000	517,000,000	-374,000,000	-259,000,000	300,000,000	444,000,000	-268,000,000	-165,000,000	187,000,000	405,000,000	-300,000,000	-19,000,000	23,000,000	226,000,000	-139,000,000	-145,000,000	303,000,000	132,000,000	-424,000,000	-223,000,000	703,000,000	181,000,000	-108,000,000	20,000,000	136,000,000	127,000,000	-85,000,000	140,000,000	-241,000,000	257,000,000	148,000,000	29,000,000	-114,000,000	246,000,000	-106,000,000	41,000,000	-77,000,000	299,000,000	-600,000,000	-535,000,000	-83,000,000	-107,000,000	175,000,000	-100,000,000	-12,000,000	111,000,000	98,000,000	256,000,000	-53,000,000	89,000,000	-99,000,000	-254,000,000	32,000,000	284,000,000	-103,000,000	350,000,000	62,000,000	238,000,000	23,000,000	-65,000,000	119,000,000
rebates and discounts	881,000,000	-627,000,000	-405,000,000	1,819,000,000	735,000,000	-665,000,000	-211,000,000	1,533,000,000	492,000,000	-910,000,000	-303,000,000	1,140,000,000	520,000,000	-930,000,000
income taxes payable	-621,000,000	54,000,000	121,000,000	-348,000,000	-1,943,000,000	910,000,000	1,044,000,000	-412,000,000	-2,119,000,000	884,000,000	-1,113,000,000	60,000,000	-1,201,000,000	831,000,000	-222,000,000	-46,000,000	-1,022,000,000	227,000,000	-201,000,000	-2,289,000,000	-44,000,000	229,000,000	860,000,000	112,000,000	-261,000,000	196,000,000	-37,000,000	-17,000,000	102,000,000	114,000,000	2,197,000,000	-65,000,000	51,000,000	414,000,000	-283,000,000	253,000,000	-520,000,000	5,000,000	-30,000,000	53,000,000	-57,000,000	81,000,000	89,000,000	273,000,000	24,000,000	-215,000,000	-2,000,000	159,000,000
other	222,000,000	-1,059,000,000	725,000,000	167,000,000	340,000,000	-608,000,000	283,000,000	-59,000,000	173,000,000	-1,064,000,000	700,000,000	-46,000,000	-191,000,000	-1,073,000,000	-627,000,000	1,065,000,000	442,000,000	-1,137,000,000	104,000,000	1,105,000,000	220,000,000	-355,000,000	17,000,000	899,000,000	718,000,000	-932,000,000	826,000,000	129,000,000	374,000,000	-695,000,000	226,000,000	154,000,000	170,000,000	-777,000,000	567,000,000	29,000,000	298,000,000	-794,000,000				-832,000,000	-17,000,000	102,000,000	96,000,000	-214,000,000	2,000,000	0	-8,000,000	-3,000,000	-56,000,000	8,000,000	3,000,000	10,000,000	80,000,000	-25,000,000	-2,000,000	-111,000,000
net cash from operating activities	3,917,000,000	1,954,000,000	4,439,000,000	5,591,000,000	2,326,000,000	2,834,000,000	4,252,000,000	4,751,000,000	1,887,000,000	2,970,000,000	3,306,000,000	3,687,000,000	2,261,000,000	3,812,000,000	4,057,000,000	5,266,000,000	3,060,000,000	3,824,000,000	3,670,000,000	2,219,000,000	4,269,000,000	3,894,000,000	2,038,000,000	2,556,000,000	2,083,000,000	1,390,000,000	2,429,000,000	1,279,000,000	1,057,000,000	1,175,000,000	1,117,000,000	1,713,000,000			1,428,000,000	1,397,000,000			611,000,000	524,000,000	71,000,000	626,000,000	572,000,000	903,000,000			1,410,000,000	1,053,000,000			836,000,000	4,584,000,000	1,134,000,000	387,000,000	1,568,000,000	1,698,000,000	1,093,000,000	481,000,000	1,595,000,000	1,383,000,000	1,049,000,000	464,000,000
cash flows from investing activities:
sale and maturities of marketable debt securities	524,000,000	220,000,000	62,000,000	238,000,000	75,000,000	747,000,000	41,000,000	365,000,000	270,000,000	57,000,000	1,206,000,000	1,417,000,000	1,688,000,000	2,100,000,000	1,244,000,000	984,000,000	1,186,000,000	782,000,000	1,523,000,000	1,220,000,000	2,143,000,000	1,394,000,000
purchase of marketable debt securities	-621,000,000	-636,000,000	-371,000,000	-40,000,000	-84,000,000	-274,000,000	-717,000,000	-502,000,000	-355,000,000	-200,000,000	-26,000,000	-274,000,000	-1,578,000,000	-1,714,000,000	-2,070,000,000	-1,065,000,000	-1,041,000,000	-1,302,000,000	-1,024,000,000	-1,191,000,000	-1,222,000,000	-735,000,000
proceeds from sales of equity investments	0	12,000,000	205,000,000	0	55,000,000	5,000,000
capital expenditures	-361,000,000	-260,000,000	-378,000,000	-324,000,000	-262,000,000	-284,000,000	-330,000,000	-342,000,000	-259,000,000	-278,000,000	-346,000,000	-247,000,000	-272,000,000	-253,000,000	-320,000,000	-270,000,000	-210,000,000	-173,000,000	-283,000,000	-153,000,000	-131,000,000	-186,000,000	-251,000,000	-190,000,000	-191,000,000	-204,000,000	-290,000,000	-224,000,000	-198,000,000	-239,000,000	-254,000,000	-262,000,000	-248,000,000	-291,000,000	-371,000,000	-341,000,000	-261,000,000	-242,000,000
free cash flows	3,556,000,000	1,694,000,000	4,061,000,000	5,267,000,000	2,064,000,000	2,550,000,000	3,922,000,000	4,409,000,000	1,628,000,000	2,692,000,000	2,960,000,000	3,440,000,000	1,989,000,000	3,559,000,000	3,737,000,000	4,996,000,000	2,850,000,000	3,651,000,000	3,387,000,000	2,066,000,000	4,138,000,000	3,708,000,000	1,787,000,000	2,366,000,000	1,892,000,000	1,186,000,000	2,139,000,000	1,055,000,000	859,000,000	936,000,000	863,000,000	1,451,000,000			1,057,000,000	1,056,000,000
divestiture and other proceeds	270,000,000	243,000,000	333,000,000	255,000,000	270,000,000	241,000,000	241,000,000	247,000,000	194,000,000	227,000,000	490,000,000	221,000,000	192,000,000	402,000,000	178,000,000	188,000,000	-203,000,000	585,000,000	320,000,000	202,000,000	143,000,000	205,000,000	13,765,000,000	1,719,000,000	197,000,000	171,000,000	302,000,000	364,000,000	208,000,000	375,000,000	196,000,000	137,000,000	148,000,000	241,000,000	141,000,000	190,000,000	564,000,000	439,000,000
acquisition and other payments, net of cash acquired	-285,000,000	-78,000,000	-47,000,000	-348,000,000	-1,373,000,000	-20,053,000,000	-581,000,000	-326,000,000	-184,000,000	-78,000,000	-116,000,000	-3,261,000,000	-467,000,000	-442,000,000	-152,000,000	-1,057,000,000	-366,000,000	-35,000,000	-12,663,000,000	-243,000,000	-153,000,000	-25,000,000
net cash from investing activities	-473,000,000	-499,000,000	-196,000,000	-219,000,000	-1,319,000,000	-19,618,000,000	-1,346,000,000	-410,000,000			1,213,000,000								-12,127,000,000	-165,000,000	780,000,000	653,000,000						-147,000,000	-348,000,000	-43,000,000								1,426,000,000				754,000,000			-1,511,000,000	2,212,000,000	-315,000,000				277,000,000	-4,203,000,000	226,000,000	-3,027,000,000	495,000,000	-163,000,000	-332,000,000	-1,437,000,000		948,000,000	238,000,000	-2,519,000,000
cash flows from financing activities:
proceeds from issuance of short-term debt obligations			0	0
repayments of short-term debt obligations			0	-269,000,000
other short-term financing obligations	58,000,000	368,000,000	-405,000,000	95,000,000
proceeds from issuance of long-term debt			0	0																																											1,477,000,000	0	0	12,000,000	0
repayments of long-term debt			0	-2,478,000,000																																				0			0	0	0	-676,000,000
dividends	-1,262,000,000	-1,258,000,000	-1,218,000,000	-1,216,000,000	-1,217,000,000	-1,212,000,000	-1,160,000,000	-1,191,000,000	-1,197,000,000	-1,196,000,000	-1,145,000,000	-1,154,000,000	-1,150,000,000	-1,185,000,000	-1,099,000,000	-1,090,000,000	-1,099,000,000	-1,108,000,000	-1,021,000,000	-1,016,000,000	-1,021,000,000	-1,017,000,000	-668,000,000	-671,000,000	-671,000,000	-669,000,000	-653,000,000	-653,000,000	-654,000,000	-653,000,000	-639,000,000	-640,000,000	-643,000,000	-655,000,000	-635,000,000	-636,000,000	-635,000,000	-641,000,000	-618,000,000	-617,000,000	-619,000,000	-623,000,000	-598,000,000	-597,000,000	-598,000,000	-605,000,000	-577,000,000	-577,000,000
stock option proceeds and other	11,000,000	-103,000,000	-19,000,000	16,000,000	-6,000,000	-97,000,000	25,000,000	41,000,000	53,000,000	-92,000,000
net cash (used in)/provided by financing activities	-1,836,000,000	-993,000,000																	3,483,000,000	-2,587,000,000																																									-495,000,000	-486,000,000
effect of exchange rates on cash, cash equivalents and restricted cash	128,000,000	66,000,000	-147,000,000	77,000,000	-22,000,000	-45,000,000	78,000,000	-38,000,000	-8,000,000	13,000,000	95,000,000	-66,000,000	-71,000,000	9,000,000	-54,000,000	-28,000,000	18,000,000	-38,000,000	87,000,000	31,000,000	60,000,000	-67,000,000
increase/(decrease) in cash, cash equivalents and restricted cash	1,736,000,000	528,000,000
cash, cash equivalents and restricted cash at beginning of period	0	10,347,000,000	0	0	0	11,519,000,000		0	0	9,325,000,000		0	0	14,316,000,000		0	0	14,973,000,000		0	0	12,820,000,000
cash, cash equivalents and restricted cash at end of period	1,736,000,000	10,875,000,000	2,454,000,000	1,597,000,000	-3,038,000,000	9,334,000,000		-857,000,000	-623,000,000	9,048,000,000		-3,003,000,000	-1,619,000,000	12,579,000,000		2,482,000,000	76,000,000	11,321,000,000		-502,000,000	4,116,000,000	16,246,000,000
net (loss)/earnings			76,000,000	1,215,000,000	1,684,000,000	-11,908,000,000															-80,000,000	-766,000,000
adjustments to reconcile net (loss)/earnings to net cash from operating activities:
repurchase of common stock							0	-4,000,000,000	-905,000,000	-250,000,000	-2,416,000,000	-585,000,000	0	-5,000,000,000	-2,751,000,000	-525,000,000	-1,236,000,000	-1,775,000,000	-1,465,000,000	0	0	-81,000,000	-7,000,000,000				0	0	-153,000,000	-167,000,000	-249,000,000	-220,000,000	0	-2,000,000,000	0	0	0	-231,000,000
net cash provided by/(used in) financing activities			-1,642,000,000	-3,852,000,000	-4,023,000,000	14,644,000,000																	-7,677,000,000	-941,000,000
(decrease)/increase in cash, cash equivalents and restricted cash																2,482,000,000	76,000,000	-3,652,000,000
adjustments to reconcile net earnings to net cash from operating activities:
decrease in cash, cash equivalents and restricted cash				1,597,000,000	-3,038,000,000	-2,185,000,000		-857,000,000	-623,000,000	-277,000,000		-3,003,000,000	-1,619,000,000	-1,737,000,000
short-term debt obligations						3,070,000,000	-353,000,000	-10,000,000	115,000,000	128,000,000	136,000,000	-72,000,000	88,000,000	42,000,000	-114,000,000	139,000,000	-123,000,000	-62,000,000	-3,000,000	-242,000,000	-48,000,000	26,000,000	16,000,000	31,000,000	157,000,000	-73,000,000	74,000,000	-71,000,000	-202,000,000	-344,000,000	-471,000,000	898,000,000
issuance of long-term debt						12,883,000,000					0	0	0	5,926,000,000									7,988,000,000	0							0	0	0	1,488,000,000					0	0
repayment of long-term debt							-2,000,000,000	0	-239,000,000	-1,640,000,000	0	-2,785,000,000	-2,877,000,000	-5,769,000,000	0	-500,000,000	-1,000,000,000	-4,522,000,000	-1,250,000,000				-8,000,000,000	0	-6,000,000	-1,250,000,000	0	0			0	-750,000,000
net earnings							1,762,000,000	1,934,000,000	2,077,000,000	2,267,000,000		1,608,000,000	1,429,000,000	1,283,000,000									-1,060,000,000	1,366,000,000	1,439,000,000	1,715,000,000	1,158,000,000	1,912,000,000	382,000,000	1,495,000,000	-2,329,000,000	856,000,000	922,000,000	1,526,000,000	898,000,000	1,215,000,000	1,188,000,000	1,206,000,000	-188,000,000	730,000,000	-110,000,000	1,199,000,000	27,000,000	732,000,000	334,000,000	936,000,000	735,000,000	692,000,000	530,000,000	623,000,000	924,000,000	-713,000,000	808,000,000	1,482,000,000	1,231,000,000	1,355,000,000	1,307,000,000	1,367,000,000	842,000,000	1,302,000,000	1,268,000,000	1,101,000,000
equity investment losses/(gains)
proceeds from sales of equity investment securities									5,000,000	62,000,000	5,000,000	63,000,000	148,000,000	2,000,000	1,521,000,000	244,000,000
net cash from financing activities							967,000,000	-5,160,000,000	-2,173,000,000	-3,050,000,000	-3,246,000,000	-4,543,000,000	-3,520,000,000	-5,653,000,000		-1,780,000,000	-3,182,000,000	-7,295,000,000				-1,054,000,000				-2,029,000,000	-578,000,000	-720,000,000	-1,015,000,000	-1,222,000,000	-1,352,000,000	-706,000,000	-1,006,000,000	-1,013,000,000	-590,000,000	-539,000,000	-524,000,000	-792,000,000	-1,086,000,000	-700,000,000	-883,000,000	-682,000,000	-231,000,000	-528,000,000	-486,000,000	-1,192,000,000	711,000,000	-620,000,000	-1,115,000,000	-44,000,000	-958,000,000	-1,689,000,000	-850,000,000	-836,000,000	-754,000,000	-704,000,000	-507,000,000	-692,000,000	-1,664,000,000
cash, cash equivalents and restricted cash at beginning of year
cash, cash equivalents and restricted cash at end of year
equity investment losses								0	58,000,000	155,000,000
net cash (used in)/provided by investing activities										-210,000,000								-143,000,000
equity investment losses/												14,000,000	308,000,000	644,000,000								339,000,000
pension settlements and amortization														7,000,000	5,000,000	5,000,000	14,000,000	11,000,000	9,000,000	12,000,000	11,000,000	11,000,000	5,000,000	1,557,000,000	60,000,000	66,000,000	41,000,000	41,000,000	54,000,000	50,000,000	88,000,000	41,000,000	55,000,000	52,000,000	47,000,000	39,000,000	44,000,000	39,000,000	67,000,000	68,000,000	60,000,000	50,000,000
net cash provided by/(used in) investing activities														95,000,000										491,000,000	715,000,000	1,060,000,000					1,019,000,000	142,000,000	-1,024,000,000	-203,000,000	16,000,000	-368,000,000			-984,000,000	-62,000,000			351,000,000						57,000,000	161,000,000
iprd charge - myokardia acquisition
asset acquisition charges															86,000,000	270,000,000	796,000,000	5,000,000	821,000,000	178,000,000			0	0			0	0	25,000,000	60,000,000	250,000,000	310,000,000			0	35,000,000	139,000,000	100,000,000
equity investment gains															469,000,000	-465,000,000										-175,000,000
increase in cash, cash equivalents and restricted cash																			-4,887,000,000	-502,000,000	4,116,000,000	3,426,000,000
deferred income																							-1,000,000	4,000,000	-6,000,000	15,000,000	0	-8,000,000	69,000,000	23,000,000	-551,000,000	-89,000,000	-76,000,000	74,000,000	-509,000,000	182,000,000	28,000,000	235,000,000	65,000,000	325,000,000	-506,000,000	334,000,000	209,000,000	-19,000,000	96,000,000	327,000,000	263,000,000	83,000,000	404,000,000	215,000,000			43,000,000	-91,000,000	4,000,000	-21,000,000	-41,000,000	-57,000,000	116,000,000	-8,000,000	-26,000,000	35,000,000
sale and maturities of marketable securities																								176,000,000	938,000,000	1,350,000,000	926,000,000	373,000,000	638,000,000	442,000,000	2,116,000,000	2,013,000,000	1,120,000,000	1,163,000,000	1,135,000,000	880,000,000	1,034,000,000	1,760,000,000	345,000,000	641,000,000								242,000,000				1,047,000,000	1,147,000,000	2,190,000,000
purchase of marketable securities																								-1,205,000,000	-195,000,000	-242,000,000	-1,243,000,000	-615,000,000	-162,000,000	-285,000,000	-1,003,000,000	-1,393,000,000	-1,837,000,000	-1,204,000,000	-841,000,000	-1,053,000,000	-672,000,000	-523,000,000
acquisition and other payments																								-9,000,000	-34,000,000	-15,000,000	-31,000,000	-45,000,000	-834,000,000	-336,000,000	-36,000,000	-353,000,000	-207,000,000	-112,000,000	-48,000,000	-44,000,000	-259,000,000	-8,000,000
effect of exchange rates on cash and cash equivalents																								-21,000,000	3,000,000	3,000,000	-12,000,000	-3,000,000	-37,000,000	11,000,000	-7,000,000	25,000,000	6,000,000	28,000,000	-49,000,000	8,000,000	-3,000,000	11,000,000	-131,000,000	14,000,000	-3,000,000	25,000,000	28,000,000			2,000,000	9,000,000	-8,000,000	14,000,000	10,000,000	-2,000,000	10,000,000	-16,000,000	7,000,000	-4,000,000	-25,000,000	6,000,000	20,000,000	0	30,000,000	-9,000,000	-7,000,000
net increase/(decrease) in cash and cash equivalents																								2,085,000,000	21,069,000,000	424,000,000
cash and cash equivalents at beginning of period																								0	0	6,911,000,000		0	0	5,421,000,000		0	0	4,237,000,000		0	0	2,385,000,000		0	0	5,571,000,000		0	0	3,586,000,000		0	0	1,656,000,000		0	0	5,776,000,000		0	0	5,033,000,000		0	0	7,683,000,000
cash and cash equivalents at end of period																								2,085,000,000	21,069,000,000	7,335,000,000		409,000,000	-343,000,000	5,342,000,000		1,174,000,000	-440,000,000	3,910,000,000		498,000,000	290,000,000	2,644,000,000		-224,000,000	-2,095,000,000	6,294,000,000		569,000,000	-943,000,000	5,225,000,000		-50,000,000	466,000,000	1,355,000,000		-1,298,000,000	494,000,000	2,307,000,000		806,000,000	260,000,000	3,405,000,000		1,663,000,000	783,000,000	5,135,000,000
loss/(gain) on equity investments																											268,000,000	-97,000,000
increase in cash and cash equivalents																																						259,000,000				723,000,000		569,000,000
cash and cash equivalents at beginning of year
cash and cash equivalents at end of year
net (decrease)/increase in cash and cash equivalents
decrease in cash and cash equivalents																													-343,000,000	-79,000,000																				-301,000,000										1,663,000,000	783,000,000	-2,548,000,000
increase/(decrease) in cash and cash equivalents																																	-440,000,000	-327,000,000	805,000,000	498,000,000			-1,590,000,000	-224,000,000						1,639,000,000	1,815,000,000	-50,000,000
adjustments to reconcile net earnings to net cash provided by/(used in) operating activities:
net cash provided by/(used in) operating activities																																		861,000,000												617,000,000				-428,000,000
short-term borrowings																																		192,000,000	23,000,000	85,000,000	50,000,000	-33,000,000	-503,000,000	-113,000,000	427,000,000	-260,000,000
interest rate swap contract terminations																																			0	0	0	42,000,000	0	0	-29,000,000	27,000,000	109,000,000	0	0	-4,000,000
issuance of common stock																																			37,000,000	12,000,000	61,000,000	71,000,000										40,000,000	173,000,000	270,000,000
adjustments to reconcile net earnings to net cash (used in)/provided by operating activities:
net cash (used in)/provided by operating activities																																						-386,000,000
net earnings attributable to noncontrolling interest																																							-9,000,000	-24,000,000			-14,000,000				-9,000,000	0	6,000,000	-14,000,000	1,000,000	2,000,000	-163,000,000	-381,000,000	-379,000,000	-386,000,000	-405,000,000	-381,000,000	-359,000,000	-353,000,000	-341,000,000	-358,000,000
other changes																																								305,000,000
purchases of marketable securities																																								-811,000,000	-651,000,000	-821,000,000	-908,000,000	-1,803,000,000	-1,928,000,000	-1,080,000,000	-411,000,000	-598,000,000	-572,000,000	-278,000,000	-106,000,000	-75,000,000	-811,000,000	-2,615,000,000	-1,475,000,000	-1,157,000,000	-1,953,000,000	-2,234,000,000	-2,120,000,000	-116,000,000	-707,000,000	-2,880,000,000
additions to property, plant and equipment and capitalized software																																								-234,000,000	-165,000,000	-136,000,000	-191,000,000	-107,000,000	-110,000,000	-118,000,000	-200,000,000	-124,000,000	-98,000,000	-115,000,000	-175,000,000	-137,000,000	-113,000,000	-123,000,000	-134,000,000	-84,000,000	-74,000,000	-75,000,000	-125,000,000	-89,000,000	-81,000,000	-129,000,000
divestitures and other proceeds																																								379,000,000
acquisitions and other payments																																								-37,000,000
issuances of common stock																																								30,000,000	27,000,000	174,000,000	59,000,000	29,000,000	28,000,000	172,000,000									236,000,000	130,000,000
net (earnings)/loss attributable to noncontrolling interest																																										-13,000,000				1,000,000
gain on sale of businesses and other																																										-234,000,000	-7,000,000
proceeds from sale and maturities of marketable securities																																										1,508,000,000	1,324,000,000	1,833,000,000	562,000,000	376,000,000				551,000,000							1,687,000,000	758,000,000	585,000,000	1,131,000,000
business divestitures and other proceeds																																										203,000,000
business acquisitions and other payments
proceeds from amylin diabetes alliance
short-term debt borrowings																																											199,000,000	40,000,000	84,000,000	-79,000,000
repurchases of common stock
proceeds from sale of businesses
other investing activities																																												123,000,000	-139,000,000	-21,000,000
proceeds from sale of business																																													104,000,000	3,055,000,000
proceeds from sale of businesses and other investing activities																																																		3,000,000					2,000,000	25,000,000	8,000,000	114,000,000
purchase of businesses, net of cash acquired																																																			0	-5,039,000,000	0	-2,491,000,000
short-term debt borrowings/																																																		551,000,000										-49,000,000
proceeds from amylin diabetes collaboration
sale of businesses and other investing activities																																																5,000,000				1,000,000	3,000,000	12,000,000
purchases of businesses, net of cash acquired
long-term debt repayments																																																			0	-1,999,000,000	0	-109,000,000	0	0	-24,000,000	-54,000,000
interest rate swap terminations																																																			0	0	0	2,000,000	0	207,000,000	85,000,000	4,000,000
common stock repurchases																																																-53,000,000	-83,000,000	-297,000,000	-492,000,000	-1,051,000,000	-521,000,000	-339,000,000	-362,000,000	-474,000,000	-237,000,000	-148,000,000	-223,000,000	-188,000,000
net change in short-term borrowings
u.s. and foreign income taxes payable																																																		77,000,000	-132,000,000	7,000,000	97,000,000	-22,000,000	-114,000,000	97,000,000	-47,000,000	-70,000,000	-49,000,000	8,000,000	-89,000,000	-106,000,000
dividends paid																																																		-580,000,000	-561,000,000	-571,000,000	-575,000,000	-579,000,000	-560,000,000	-564,000,000	-565,000,000	-565,000,000	-549,000,000	-550,000,000	-552,000,000	-551,000,000
other deferred income																																																			195,000,000
deferred income from diabetes collaboration
short-term borrowings/																																																				-101,000,000	91,000,000	30,000,000		-3,000,000	52,000,000	18,000,000
stock option exercises																																																				83,000,000	155,000,000	159,000,000
depreciation																																																					90,000,000	85,000,000	115,000,000	105,000,000	111,000,000	117,000,000	125,000,000	102,000,000	124,000,000	122,000,000
amortization																																																					102,000,000	101,000,000	92,000,000	93,000,000	95,000,000	73,000,000	73,000,000	66,000,000	67,000,000	65,000,000
deferred income tax expense																																																					-124,000,000	204,000,000	142,000,000	30,000,000	66,000,000	177,000,000
stock-based compensation expense																																																					40,000,000	42,000,000	41,000,000	39,000,000	43,000,000	38,000,000
(decrease)/increase in cash and cash equivalents																																																					494,000,000	-3,469,000,000		806,000,000	260,000,000	-1,628,000,000
gain related to divestitures of discontinued operations
mead johnson’s cash at split-off
short-term debt repayments
long-term debt borrowings																																																											0	0
proceeds from mead johnson initial public offering
proceeds from sales and maturities of marketable securities
purchase of amira pharmaceuticals, inc., net of cash acquired
issuances of common stock and excess tax benefits from share-based arrangements																																																										53,000,000	41,000,000	89,000,000	40,000,000	82,000,000
acquired in-process research and development
gain on sale of imclone shares
other gains																																																											2,000,000	-19,000,000	-5,000,000	-10,000,000
proceeds from sale of businesses, property, plant and equipment and other investments																																																											10,000,000	22,000,000	-2,000,000	37,000,000
proceeds from divestitures of discontinued operations
proceeds from sale of imclone shares
proceeds from sale and leaseback of properties
impairment of manufacturing operations																																																												7,000,000
changes in other operating assets and liabilities																																																												322,000,000	-182,000,000	-557,000,000
purchase of medarex, inc., net of cash acquired
interest rate swap termination																																																												0
impairment charge																																																														200,000,000
proceeds from sale of marketable securities																																																														453,000,000
short-term debt (repayments)/borrowings																																																														-17,000,000

We provide you with 20 years of cash flow statements for Bristol-Myers Squibb stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as operating cash flows, cash levels, capital expenditures, profits, stock-based compensations and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Bristol-Myers Squibb stock. Explore the full financial landscape of Bristol-Myers Squibb stock with our expertly curated income statements.

The information provided in this report about Bristol-Myers Squibb stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.